Cellectar reports single‑dose iopofosine I‑131 yields over eight‑year complete response in DLBCL patient
+1 new source since this summary was written
Cellectar Biosciences disclosed that a 53‑year‑old patient with heavily pretreated diffuse large B‑cell lymphoma achieved a complete response after a single 57.5 mCi dose of iopofosine I‑131 administered in March 2018. The response has persisted for more than eight years with no disease progression or additional therapy as of May 2026. The company said it will begin dosing in its confirmatory Phase 3 Waldenström macroglobulinemia study in the first quarter of 2027 and plans an accelerated FDA filing in the first half of 2027.
Why it matters
The durable response provides additional clinical evidence supporting iopofosine I‑131’s mechanism and may strengthen investor confidence ahead of the Phase 3 start and FDA submission, which could affect CLRB’s valuation.
Key facts
- 1The patient received a single 57.5 mCi dose of iopofosine I‑131 on March 20, 2018. stocktitan.net
- 2A complete response was confirmed by Day 85, with the target lesion shrinking from 825 mm³ to 0 mm³. stocktitan.net
- 3As of May 2026, more than eight years after treatment, the patient has had no disease progression and required no further anticancer therapy. stocktitan.net
- 4Cellectar plans to initiate patient dosing in its confirmatory Phase 3 Waldenström macroglobulinemia study in Q1 2027. rttnews.com
- 5The company expects to submit an accelerated FDA application for iopofosine I‑131 in the first half of 2027. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.